Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cethrin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BA-210 (cethrin) is a first-in-class, topically applied, biologic Rho inhibitor, developed BA-210 to inactivate Rho and has brought the compound forward to clinical testing. BA-210 has both orphan drug status and Fast Track designation from the FDA.
Brand Name : BA-210
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 22, 2022
Lead Product(s) : Cethrin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BA-1049
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Neurelis
Deal Size : Undisclosed
Deal Type : Acquisition
Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds
Details : Neurelis intends to submit an Investigational New Drug (IND) application with the FDA on BioAxone's lead compound, BA-1049, in 2022. BioAxone's lead product, BA-1049, offers an opportunity to treat CCMs by stabilizing lesions and by preventing new lesio...
Brand Name : BA-1049
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 21, 2021
Lead Product(s) : BA-1049
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Neurelis
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : BA-1049
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.
Brand Name : BA-1049
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 28, 2020
Lead Product(s) : BA-1049
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?